A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) an dCD30-expressing Peripheral T-cell Lymphoma (PTCL) in Older Patients or Patients With Significant Comorbidities Ineligible for Standard Chemotherapy
Latest Information Update: 12 Jun 2024
At a glance
- Drugs Brentuximab vedotin (Primary) ; Bendamustine; Dacarbazine; Nivolumab
- Indications Hodgkin's disease; Peripheral T-cell lymphoma
- Focus Therapeutic Use
- Sponsors Seagen
- 21 Dec 2023 According to American Oncology Network media release, data from the study were presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition.
- 12 Dec 2023 Results (n=30) efficacy and safety of single-agent BV as frontline therapy in cHL pts who are ineligible for conventional combination chemotherapy because of comorbidities in part E, presented at the 65th American Society of Hematology Annual Meeting and Exposition.
- 09 Nov 2023 Results published in the Blood